Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47493
Title: | Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis | Authors: | Maneechotesuwan K. Singh D. Fritscher L.G. Dursunoğlu, N. Abhijith P.G. Phansalkar A. Aggarwal B. Pizzichini, Emilio Chorazy, Justyna Burnett, Heather |
Keywords: | Asthma quality of life questionnaire ICS/LABA Network meta-analysis Systematic review fluticasone propionate plus salmeterol bronchodilating agent corticosteroid fluticasone fluticasone propionate plus salmeterol formoterol fumarate adolescent adult asthma Asthma Control Questionnaire Asthma Quality of Life Questionnaire child female follow up forced expiratory volume human lung function male meta analysis monotherapy multicenter study (topic) network meta-analysis quality of life randomized controlled trial (topic) Review severe asthma systematic review asthma Bayes theorem drug combination inhalational drug administration Administration, Inhalation Adrenal Cortex Hormones Asthma Bayes Theorem Bronchodilator Agents Drug Combinations Fluticasone Fluticasone-Salmeterol Drug Combination Formoterol Fumarate Humans Network Meta-Analysis Quality of Life |
Publisher: | W.B. Saunders Ltd | Abstract: | Objective: This network meta-analysis (NMA) compared fixed-dose, twice daily fluticasone propionate/salmeterol (FP/Sal) vs. inhaled corticosteroid (ICS) and other ICS/long-acting beta-agonists (LABA) treatments, including when administered using maintenance and reliever therapy (MART) regimens, in terms of improvements in health-related quality of life (HRQoL). The relationship between changes in asthma control and HRQoL was assessed. Methods: Articles published between 2001 and 2021, reporting change from baseline (CFB) in Asthma Quality of Life Questionnaire (AQLQ) in patients with moderate-to-severe asthma, were identified by a systematic review. Random effects Bayesian NMAs derived estimates of the mean difference in CFB in AQLQ vs. other interventions connected to the network (included 15 studies). Sensitivity analyses explored the impacts of differences in follow-up duration, baseline asthma control, the inclusion of observational studies, adjusting for baseline FEV1, and low-medium ICS dose arms only. Linear regression analysis compared CFBs in AQLQ and Asthma Control Questionnaire (ACQ) score. Results: Mean CFB in AQLQ with FP/Sal vs. comparators demonstrated expected ranked effects: mean difference 0.65 [95% credible interval: 0.54, 0.78] versus placebo, 0.58 [ 0.33, 0.84] versus LABA, 0.21 [ 0.13, 0.31] versus ICS alone, 0.06 [?0.04, 0.19] versus other ICS/LABA, and 0.00 [?0.13, 0.14] versus ICS/formoterol MART. Sensitivity analyses largely showed consistent results. Improvements in AQLQ and ACQ were strongly correlated (R = 0.94). Conclusions: This NMA demonstrates that HRQoL is responsive to treatment, is strongly related to asthma control and that it can be well-managed in patients with moderate-to-severe asthma using regular treatment with inhaled FP/Sal. © 2022 The Authors | URI: | https://doi.org/10.1016/j.rmed.2022.106993 https://hdl.handle.net/11499/47493 |
ISSN: | 0954-6111 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
4
checked on Oct 13, 2024
WEB OF SCIENCETM
Citations
3
checked on Oct 31, 2024
Page view(s)
66
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.